Medicines and medical devices for 10 000 people for approximately three months
as of 12:00 AM, 17 September 2018 - 6:00 AM, 17 September 2018
Last revised 2015.
Original Word document on: http://www.epnetwork.org/Resources/Standard%20Operating%20Procedure/Determinants%20of%20damaged%20or%20poor%20quality%20supplies_SOP.doc
STATUTORY INSTRUMENTS | SUPPLEMENT No. 8 28th March, 2014 | STATUTORY INSTRUMENTS SUPPLEMENT | to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 | Printed by UPPC, Entebbe, by Order of the Government. | STATUTORY INSTRUMENTS | 2014 No. 29.
Depuis son apparition début décembre 2019 en Chine, la pandémie de coronavirus (CoViD19), une nouvelle forme de syndrome respiratoire aigu sévère, s'est propagée dans le monde entier avec une rapidité sans précédent. Le 30 janvier 2020, l'Organisation mondiale de la santé (OMS) a déclaré... l'épidémie comme une urgence sanitaire internationale, suivie par la déclaration de la pandémie le 11 mars 2020, rendant obligatoire pour tous les pays de surveiller en permanence la situation et de mettre en œuvre des mesures de prévention et de réponse.
more
How to recognise Post-Traumatic Stress Disorder | The nature and cause of Post-Traumatic Stress Disorder | Treatment and referral | Sources of further information | Compiled by the Scientific & Advisory Board Members of the South African Depression & Anxiety Group, and reviewed by the MRC Research U...nit on Anxiety and Stress Disorders
more
Accessed: 25.04.2020
La République démocratique du Congo connaît une situation d’urgence complexe, aggravée par de multiples crises aiguës depuis plus de deux décennies. La dégradation de la situation humanitaire a provoqué une crise aiguë plongeant 15,6 millions de personnes dans les ...besoins d’assistance humanitaire en 20201 dont 8,1 millions ciblés par le Plan de Réponse Humanitaire en 2020. En plus de cette crise humanitaire, la RDC fait face à une crise sanitaire due à la pandémie de la maladie à coronavirus (COVID-19) depuis le 10 mars 2020.
more
This FAQ responds to questions revolving around the topic of protecting refugee women and girls against violence. It begins with a glossary that clarifies key terms and their consequences for female refugees. The glossary will be amended and updated as required on the websites of b...ff and FHK.
more
An Act to repeal the Dangerous Medicines Act of 1973,to ensure the availability of certain drugs for exclusive medical, scientific and related purposes, while preventing their abuse; to prevent the diversion from lawful trade of controlled chemicals, controlled equipment and controlled materials for... use in the unlawful manufacture of such drugs; to render drug trafficking and related conduct as serious criminal offences and to ensure that trafficking and related conducted as serious criminal offences and to ensure that offenders or suspects are brought to justice; to render certain conduct by drug users as criminal offences, to provide for the treatment and rehabilitation of drug abusing or dependent offenders; to establish the Lesotho Narcotics Bureau; and for related matters.
more
UN human rights experts today called on States to protect the rights of migrants and their families, regardless of their migration status, during and after the COVID-19 pandemic.
Plan stratégique 2022-2030 de l’ICTC
Brochure on 'increase in the risk of violence against older people' and what can be done to adress it.
Therapy for MDR-TB is extremely long, complex and burdensome to both patients and health care systems. A single diagnosis can require two years of treatment, or longer. When treating children, there are significant additional barriers treating children with MDR-TB. There is limited data on the pharm...acokinetics of second-line TB drugs in children, and almost none are in child-friendly formulations. Nonetheless, there is continued work on second-line drugs to fight MDR-TB. The Sentinel Project has created a complex set of dosing recommendations for administering second-line drugs to children
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more